Japan Reinforces LMO Safety Regulations for Advanced Biotech Research and Regenerative Medicine

厚生労働省 Japan

Overview

Japan’s Ministry of Health, Labour and Welfare (MHLW) has reissued critical guidelines on the contained use (Type 2) of living modified organisms (LMOs) under the Cartagena Act. This re-notification emphasizes strict adherence to safety management protocols, facility requirements, and reporting obligations for research institutions and companies leveraging genetic modification technologies, particularly in gene therapy and regenerative medicine. The move aims to balance scientific innovation with robust biodiversity protection and public trust in Japan’s rapidly advancing life sciences sector.

In Depth

Background

While genetic modification technology drives innovative advancements in medicine, agriculture, and industry, its application also raises concerns about potential impacts on biological diversity and human health. Japan’s ‘Act on the Conservation and Sustainable Use of Biological Diversity through Regulations on the Use of Living Modified Organisms’ (commonly known as the Cartagena Act) was enacted based on the international Cartagena Protocol, aiming to manage these risks and conserve biodiversity. With the rapid development of regenerative medicine and gene therapy, there is an increasing trend in the development of therapies utilizing genetically modified iPSCs and gene-edited cells. Safe handling of these products and preventing their unintended release into the environment are paramount. The MHLW’s re-notification is part of continuous efforts to ensure that relevant operators are always aware of and comply with the latest safety management standards as technology advances.

Key Findings

On June 5, 2026, the Ministry of Health, Labour and Welfare (MHLW) of Japan announced a re-notification concerning Type 2 Use and other notifications for living modified organisms (LMOs) under the Cartagena Act. This administrative measure aims to reiterate the importance of compliance with relevant regulatory requirements for institutions engaged in research and industrial applications involving genetically modified technologies.

Technical Details and Regulatory Scope

The Cartagena Act categorizes the use of LMOs into ‘Type 1 Use’ (without containment measures) and ‘Type 2 Use’ (with containment measures), applying different regulations based on risk levels. This re-notification primarily focuses on ‘Type 2 Use,’ which involves handling LMOs in contained systems such as laboratories, factories, and experimental fields. Examples include genetic therapy research utilizing pathogenic vectors, genetic modification of induced pluripotent stem cells (iPSCs), and the use of LMOs in regenerative medicine product development. The notification re-emphasizes the need for operators to adhere to specified containment levels, proper facility management, secure waste disposal, and robust emergency response plans in these research and development activities.

Industry Implications and Future Outlook

This re-notification highlights the critical importance for all operators within Japan’s life sciences sector to correctly understand regulations and implement appropriate safety management measures as research and development using genetic modification technology continues to be active. Strict compliance with regulations is essential for maintaining public trust and supporting future technological innovation. Companies developing regenerative medicine products are strongly urged to re-evaluate their internal safety management systems and submit necessary notifications without delay. This proactive adherence will enable Japan to maintain its position as a global leader in promoting the safe development and practical application of innovative regenerative medicine and gene therapy products.